Follow the Pundits
Tag: #FUNanc1al
D.E. Shaw’s 2025 Scorecard: Put on Quite a Show With AI and Quants
D.E. Shaw put on a quant-powered show in 2025 — and quietly built a private-credit fortress for what comes next.
AQR Capital’s 2025 Scorecard: From Applied Quantitative Research to Actually Quality Returns
AQR Capital’s machines finally had their year. Strong 2025 returns across quant strategies prove factors aren’t dead — they just needed faster computers.
Pershing Square Rounds Up a Strong 2025: High Conviction, Concentrated Bets — and Real Outperformance
Pershing Square’s concentrated, high-conviction strategy paid off in 2025. Fewer bets, bigger opinions — and real outperformance.
Berkshire Hathaway's 2025 Scorecard: Defensive Portfolio, Slightly Underwhelming Performance — But a Historic Transition
Berkshire played defense in 2025: record cash, cautious positioning, and the end of an era as Warren Buffett stepped aside. Solid, sober, and very Berkshire.
Kenvue Director Jeff Smith of Starboard Value Buys Shares of KVUE; He Must Love Kimberly-Clark. Should You?
A $111 million insider buy. Nearly 100% institutional ownership. A blockbuster merger with Kimberly-Clark. Kenvue suddenly looks boring… in a very interesting way.
New CEO and Activist Corvex’s Keith Meister Buy Vestis; Expect Profits or Casual Tees?
A new CEO with UPS DNA, millions in insider buys, and activist hedge fund Corvex circling… Vestis stock checks many contrarian boxes. But high leverage and a slow turnaround mean this is not for the faint of heart. 👕📈
Alfred Lin of Sequoia Capital Buys $100 Million Worth of DoorDash Stock. Will The Shares Deliver?
When Sequoia’s Alfred Lin drops a $100M insider buy on DoorDash, investors pay attention. DASH is growing fast, expanding globally, and courting robots — but is the stock about to deliver… or disappoint?
Biotech Venture Capital Firm Casdin Keeps Buying Standard BioTools Shares — Time To Invest, Or Time To Label This “Highly Experimental”?
Casdin Capital just scooped up over a million shares of Standard BioTools — again. With strong tech, big cash coming from Illumina, and a major restructuring underway, is this small-cap biotech tools maker a deep-value setup or just another “high-risk, high-lab-cost” gamble? Here’s what’s really going on.
Key Director and Bessemer Partner Buys Over $5M of ACV Auctions: Time to Bid, or Just Mor-Bid Curiosity?
A major insider just snapped up 912,408 shares of ACV Auctions—over $5.1 million worth. Institutions are stuffed with shares, revenue is growing nearly 20%, and profits are inching closer. Should investors bid… or back away slowly?
Amazon Is ValueAct Holdings’ Top Holding. Should You Buy?
ValueAct didn’t nibble—Amazon is its top holding. Under the hood: AWS growth, retail media margins, and AI making robots, delivery, and dev tools smarter. Not cheap—but quality compounding can justify the tag. Read our Quick Take, risks box, and how to buy dips with a cool head.